Two new monoclonalantibodies were approved by the fda in August

Share This Post

👉 elranatamab bcmm, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and, 

👉 pozelimab bbfg, to treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease

The role of recombinant proteins in the fight against cancer and geneticdisorders of the immunesystem has become in recent years of fundamental importance, providing novel solutions to the medical community and great hope for patients. 

Novel drugs’ approvals are the fruit of ambitious and complex researchanddevelopment programs from the early, discovery, phase till clinical evaluation of safety and efficacy. 

We, at Magellan Biologics & Consulting support 👉 YOU, research scientists from all around the world involved in the production of recombinant proteins for screening at discovery stage. Our CHO4Tx® system (optimized CHO cell line, media and protocol) is widely recognized as making protein 
expression in CHO cells easy, efficient and cost-effective. 

Get updates

Subscribe To Our Newsletter

More To Explore

Interested in our products?

Drop us a line and keep in touch

Your cart is currently empty.

Welcome on board!

Subrscribe to our Newsletter
and stay updated!

Get Updates!

If you opt in above we use this information send related content